Toth Financial Advisory Corp Decreases Stock Holdings in Abbott Laboratories $ABT

Toth Financial Advisory Corp lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 18.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,196 shares of the healthcare product maker’s stock after selling 20,574 shares during the period. Toth Financial Advisory Corp’s holdings in Abbott Laboratories were worth $8,366,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories during the fourth quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the fourth quarter valued at approximately $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on ABT shares. Sanford C. Bernstein lowered their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Benchmark decreased their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Piper Sandler reiterated an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. TD Cowen restated a “buy” rating and set a $115.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Bank of America reduced their price objective on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $118.67.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $111.37 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The stock has a market capitalization of $192.71 billion, a price-to-earnings ratio of 36.04, a PEG ratio of 2.15 and a beta of 0.59. The company has a 50-day simple moving average of $97.27 and a 200-day simple moving average of $99.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wolfe Research upgraded Abbott Laboratories (ABT) from “peer perform” to “outperform” and set a $130 target, implying substantial upside from recent trading levels. Benzinga analyst upgrade report
• Positive Sentiment: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market growth, broad branded-generic offerings and resilient healthcare demand. Expanding biosimilar opportunities could provide an additional long-term growth avenue. Zacks EPD growth report
• Positive Sentiment: Abbott and Google Health announced a multiyear partnership to integrate Abbott’s Lingo continuous glucose-monitoring data into Google’s AI-powered consumer health tools. The collaboration could increase Lingo’s visibility, support personalized metabolic-health services and generate valuable real-world data. Abbott and Google Health Lingo partnership
• Positive Sentiment: Bank of America Securities issued a “buy” recommendation for ABT, reinforcing the constructive Wall Street view. Bank of America buy rating
• Neutral Sentiment: Abbott’s stock outperformed competitors during a strong broader trading session, reflecting market momentum but not a new company-specific fundamental catalyst. MarketWatch trading report
• Neutral Sentiment: Abbott’s PULSE study is evaluating earlier treatment for atrial fibrillation. Positive clinical results could expand future device demand, but the study remains ongoing and carries execution and clinical risk. TipRanks PULSE study report
• Neutral Sentiment: Abbott renewed its blood-donation campaign with the Big Ten amid a U.S. blood shortage. The initiative supports Abbott’s brand and blood-management business, though its direct near-term financial impact is likely limited. Abbott and Big Ten blood donation campaign

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.